Navigation Links
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
Date:8/19/2008

NEW HAVEN, Conn., Aug. 19 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(R) (VNP40101M)) with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS).

Alan Kessman, Chief Executive Officer, commented, "We are pleased to be working with HOVON, one of the most prestigious clinical groups in hematology oncology. We continue to believe that Cloretazine(R) will have broad utility in the treatment of hematological malignancies as both a single agent and in combination with other therapies. This trial will provide important data with regard to Cloretazine(R)'s utility in the treatment of AML when given in combination with standard remission-induction therapy for this devastating disease."

Dr. Bob Lowenberg, Chief Investigator of HOVON, said, "HOVON is focusing on the clinical development of new therapeutic options for patients with leukemia. Laromustine is a promising agent for that effort."

The trial has been designed as a Phase III study in two parts. Part A will determine the feasibility (based on safety and preliminary effectiveness) of laromustine administration at three possible dose levels in combination with cytarabine and idarubicin. Part A will also evaluate the pharmacokinetics and the clinical efficacy of the laromustine combination.

Part B is then designed to evaluate the clinical efficacy of the laromustine combination versus two cycles of cytarabine and idarubicin without laromustine with regard to clinical outcome ("event free survival"), the complete remission rate, disease free survival (DFS), risk of relapse and overall survival (OS), as well as the tolerance and toxicity, and pharmacokinetics of the combin
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)...olled in Clinical Trial to Assess Survival of Pati...ies for Unresectable Hepatocellular Carcinoma , ...ght Sciences Oncology, Inc. (LSO) today announced ...linical trial of Light Infusion Therapy(TM) (Litx(...r carcinoma (HCC), also known as hepatoma or prima...
(Date:11/24/2008)..., Nov. 24 Domino,s Pizza (NYSE: ...ery, is gearing up to raise dough for,the kids of...fifth annual,Thanks and Giving campaign. Domino,s...nation at point of purchase to benefit the childre...g over the phone or when ordering online at, www....
(Date:11/24/2008)...s its innovation leadership and long-term commitme...J., Nov. 24 Schering-Plo...inical update on boceprevir, its lead investigatio...in Phase III development. The company believes bo...and best-in-class protease inhibitor for treating ...
(Date:11/24/2008)... /PRNewswire-FirstCall/ - Predictive medicine comp...d that it has entered into a fully funded collabor...st cosmetic companies. PreMD,s PREVU* skin cholest...the cosmetic company,s skin care products in a Eur...essful study completed by PreMD with the cosmetic ...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate 2Use of information technology is minimal in nursing homes 16245 1Use of information technology is minimal in nursing homes 16245 2Ancient DNA 3A reconstruction of the biological history of Aldaieta necropolis 2811 1Ancient DNA 3A reconstruction of the biological history of Aldaieta necropolis 2811 2Ancient DNA 3A reconstruction of the biological history of Aldaieta necropolis 2811 3Distance learning course in radiation oncology for cancer treatment 2809 1Distance learning course in radiation oncology for cancer treatment 2809 2American Society for Microbiology 108th General Meeting 2807 1American Society for Microbiology 108th General Meeting 2807 2
... CHAPEL HILL, N.C., US, March 06, 2007,/PRNewswire...and,Lantibio, Inc. ("Lantibio") today announced po..., double-blinded Phase II clinical,study of Moli19...sis ("CF"). Moli1901 is being developed by AOP Orp...ion agreement with,Lantibio. The study, performed ...
...SS WIRE)--Mar 7, 2007 - Accentia,Biopharmaceutical...,the Annual Meeting of the American Academy of All..., 2007 in San Diego, CA. The,posters discussed fin...) and allergists in the U.S., U.K., France, and Ge... knowledge and attitudes of,the fungal etiology of...
Other Medicine Technology:AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: